Literature DB >> 3210014

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

E Sofic1, P Riederer, H Heinsen, H Beckmann, G P Reynolds, G Hebenstreit, M B Youdim.   

Abstract

Significant differences in the content of iron (III) and total iron were found in post mortem substantia nigra of Parkinson's disease. There was an increase of 176% in the levels of total iron and 225% of iron (III) in the substantia nigra of the parkinsonian patients compared to age matched controls. In the cortex (Brodmann area 21), hippocampus, putamen, and globus pallidus there was no significant difference in the levels of iron (III) and total iron. Thus the changes in total iron, iron (III) and the iron (II)/iron (III) ratio in the parkinsonian substantia nigra are likely to be involved in the pathophysiology and treatment of this disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3210014     DOI: 10.1007/bf01244786

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  18 in total

1.  CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.

Authors:  P Riederer; W D Rausch; W Birkmayer; K Jellinger; D Seemann
Journal:  J Neural Transm Suppl       Date:  1978

2.  Study of movement disorders and brain iron by MR.

Authors:  J N Rutledge; S K Hilal; A J Silver; R Defendini; S Fahn
Journal:  AJR Am J Roentgenol       Date:  1987-08       Impact factor: 3.959

Review 3.  Biochemical fundamentals of Parkinson's disease.

Authors:  P Riederer; W D Rausch; B Schmidt; P Kruzik; C Konradi; E Sofić; W Danielczyk; M Fischer; E Ogris
Journal:  Mt Sinai J Med       Date:  1988-01

4.  Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue.

Authors:  K M Earle
Journal:  J Neuropathol Exp Neurol       Date:  1968-01       Impact factor: 3.685

5.  Increased nigral iron content in postmortem parkinsonian brain.

Authors:  D T Dexter; F R Wells; F Agid; Y Agid; A J Lees; P Jenner; C D Marsden
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

6.  Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.

Authors:  P Riederer; E Sofic; W D Rausch; B Schmidt; G P Reynolds; K Jellinger; M B Youdim
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

7.  Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.

Authors:  T Nagatsu; T Kato; Y Numata; K Ikuta; M Sano
Journal:  Clin Chim Acta       Date:  1977-03-01       Impact factor: 3.786

8.  Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay.

Authors:  T Nagatsu; T Yamaguchi; T Kato; T Sugimoto; S Matsuura; M Akino; I Nagatsu; R Iizuka; H Narabayashi
Journal:  Clin Chim Acta       Date:  1981-02-05       Impact factor: 3.786

9.  Iron, a new aid in the treatment of Parkinson patients.

Authors:  W Birkmayer; J G Birkmayer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

10.  Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron.

Authors:  B P Drayer; W Olanow; P Burger; G A Johnson; R Herfkens; S Riederer
Journal:  Radiology       Date:  1986-05       Impact factor: 11.105

View more
  166 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

3.  Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.

Authors:  R Pedrosa; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 4.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

5.  Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+).

Authors:  Francisco J Gómez; Pabla Aguirre; Christian Gonzalez-Billault; Marco T Núñez
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

6.  Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system.

Authors:  M Eapen; D H Zald; J C Gatenby; Z Ding; J C Gore
Journal:  AJNR Am J Neuroradiol       Date:  2010-12-23       Impact factor: 3.825

Review 7.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

8.  Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Authors:  Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

9.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

10.  Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia.

Authors:  William Lin; Natasha L Wadlington; Linan Chen; Xiaoxi Zhuang; James R Brorson; Un Jung Kang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.